mirikizumab
Selected indexed studies
- Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. (Lancet, 2024) [PMID:39581202]
- Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. (N Engl J Med, 2023) [PMID:37379135]
- Mirikizumab. (, 2006) [PMID:38051795]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Mirikizumab: First Approval. (2023) pubmed
- Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme. (2024) pubmed
- Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study. (2024) pubmed
- Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. (2023) pubmed
- Mirikizumab. (2006) pubmed
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. (2022) pubmed
- Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis. (2024) pubmed
- Mirikizumab for the treatment of moderate to severe ulcerative colitis. (2023) pubmed
- Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. (2024) pubmed
- Mirikizumab-mrkz. (2024) pubmed